Medite Cancer Diagnostics, Inc.: key financial figures for fiscal year 2017 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2017)
- $6.8M
- Net Income/Loss (FY2017)
- -$6.8M
- Total Assets (FY2017)
- $16.0M
- Total Equity (FY2017)
- $5.8M
- Cash Flows from Operating Activities (FY2017)
- -$3.6M
Source: Medite Cancer Diagnostics, Inc. 10-K filing (FY2017). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
